Shares of Masimo Co. (NASDAQ:MASI) have been given a consensus recommendation of “Buy” by the eight ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $139.13.
MASI has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $139.00 price target on shares of Masimo in a report on Friday, February 1st. Zacks Investment Research downgraded shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 31st. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Masimo in a report on Wednesday, February 27th. Finally, BTIG Research downgraded shares of Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target on the stock. in a report on Tuesday, April 16th.
In related news, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 74,832 shares of the company’s stock, valued at $10,102,320. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jon Coleman sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $130.00, for a total transaction of $260,000.00. Following the transaction, the insider now directly owns 13,201 shares of the company’s stock, valued at approximately $1,716,130. The disclosure for this sale can be found here. In the last three months, insiders sold 35,722 shares of company stock valued at $4,832,310. Company insiders own 11.50% of the company’s stock.
Shares of NASDAQ MASI traded up $3.53 on Thursday, hitting $127.11. The company’s stock had a trading volume of 36,955 shares, compared to its average volume of 437,543. Masimo has a 12-month low of $88.09 and a 12-month high of $141.05. The company has a market capitalization of $6.59 billion, a PE ratio of 41.94, a price-to-earnings-growth ratio of 2.55 and a beta of 1.19.
Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.11. Masimo had a net margin of 22.55% and a return on equity of 19.53%. The company had revenue of $223.10 million for the quarter, compared to the consensus estimate of $220.96 million. During the same quarter in the prior year, the firm earned $0.72 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, equities research analysts expect that Masimo will post 3.08 earnings per share for the current fiscal year.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: Do stock splits help investors?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.